Apremilast Demonstrates Sustained Efficacy in Moderate to Severe Genital Psoriasis Through 32 Weeks
核心洞察
Apremilast showed sustained clinical efficacy in treating moderate to severe genital psoriasis (搜索) at 32 weeks, with 51.8% of patients achieving modified genital PGA response after switching from placebo.
The DISCREET phase 3 trial demonstrated comparable improvements in skin disease, genital psoriasis (搜索) symptoms, and quality-of-life measures between continuous treatment and delayed-start groups.
Safety profile remained consistent with previous studies, with diarrhea (25.4%), nausea (19.4%), and headaches (17.9%) being the most commonly reported adverse events.
Apremilast, an oral phosphodiesterase-4 (搜索) (PDE4 (搜索)) inhibitor, has demonstrated sustained clinical efficacy in treating moderate to severe genital psoriasis (搜索) through 32 weeks of treatment, according to extended results from the phase 3 DISCREET study. The findings support apremilast as an effective oral systemic therapy for this challenging condition, with consistent improvements in clinical outcomes and quality of life measures.
Extended Trial Results Show Durable Response
The 32-week analysis of the DISCREET trial (NCT03777436) revealed that 51.8% of patients who switched from placebo to apremilast at week 16 achieved a modified genital PGA response, defined as a score of 0 or 1 with at least a 2-point reduction from baseline (95% CI: 42.6–60.9). Among patients who received continuous apremilast treatment throughout the study, 40.3% achieved this response (95% CI: 32.0–49.3).
"Based on the consistent clinical efficacy, improvements in symptoms and QoL benefit seen in DISCREET, apremilast appears to be an effective oral therapy in patients with moderate to severe genital psoriasis (搜索)," wrote the investigators led by Joseph F. Merola, MD, MMSc, of UT Southwestern Medical Center (搜索).
Study Design and Patient Population
The randomized, double-blind, placebo-controlled trial was conducted across multiple centers in Canada, Belgium, France, Italy, the United States, and Germany. A total of 289 patients were randomized in a 1:1 ratio to receive either apremilast 30 mg twice daily or matched placebo for 16 weeks, followed by a 16-week extension phase where all participants received apremilast.
Eligible participants were adults with moderate to severe genital psoriasis (搜索), indicated by a baseline modified static Physician's Global Assessment of Genitalia (genital PGA or sPGA-G) score of 3 or higher. All patients had either insufficient response to or intolerance of topical drugs and also had moderate to severe chronic plaque psoriasis (搜索) for at least six months, with non-genital plaque psoriasis involving at least 1% of body surface area.
Of the 289 randomized patients, 229 entered the apremilast extension period, with 110 transitioning from placebo to apremilast at week 16 and 119 continuing on apremilast throughout the full 32-week period.
Comparable Outcomes Across Treatment Groups
By the study's conclusion at 32 weeks, investigators identified improvements in overall skin disease, genital psoriasis (搜索) signs and symptoms, and quality-of-life measures that were comparable between subjects who initiated apremilast at randomization and those who began treatment at the 16-week mark. This finding suggests that the therapeutic benefits of apremilast can be achieved regardless of treatment timing within the study period.
Safety Profile Remains Consistent
The safety analysis revealed that the most commonly reported treatment-emergent adverse events during apremilast exposure were diarrhea (25.4%), nausea (19.4%), and headaches (17.9%). These findings align with the established safety profile of apremilast from previous clinical studies.
Regulatory Impact and Clinical Significance
The positive results have led to regulatory recognition, with product labeling in the United States being revised to include efficacy data supporting apremilast's use in genital psoriasis (搜索). This represents an important advancement for patients with this condition, who often have limited treatment options beyond topical therapies.
The DISCREET study builds upon earlier 16-week results that initially demonstrated apremilast's safety and efficacy in treating genital psoriasis (搜索), providing healthcare providers with extended data on the medication's sustained therapeutic benefits in this patient population.